VPValentina Perini

Valentina Perini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valentina Perini has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Deborah J. Keszenman

    Grupo de Biofisicoquímica, Departamento de Ciencias Biológicas, Centro Universitario Regional Litoral Norte, Universidad de la República, Salto 50000, Uruguay

    1 shared publication
  • Diego Alem

    Epigenetics and Genomic Instability Laboratory, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay

    1 shared publication
  • Gloria V. Lopez

    Organic Synthesis and Drug Development Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay; Departamento de Química Orgánica, Facultad de Química, Universidad de La República, Montevideo, Uruguay

    1 shared publication
  • Karen Perelmuter

    Cell Biology Unit, Institut Pasteur de Montevideo, Mataojo 2020, Montevideo 11400, Uruguay

    1 shared publication
  • Laura Lafon-Hughes

    Grupo de Biofisicoquímica, Departamento de Ciencias Biológicas, Centro Universitario Regional Litoral Norte, Universidad de la República, Salto, Uruguay

    1 shared publication
  • Mariana Ingold

    Laboratorio de Biología Vascular y Desarrollo de Fármacos, Institut Pasteur Montevideo, Mataojo 2020, Montevideo 11400, Uruguay

    1 shared publication

Latest Publications

  • Open Access

    New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs

    by María Varela, Miriam López, Mariana Ingold, Diego Alem, Valentina Perini, Karen Perelmuter, Mariela Bollati-Fogolín, Gloria V. López, Paola Hernández

    Bladder cancer is a worldwide problem and improved therapies are urgently needed. In the search for newer strong antitumor compounds, herein, we present the study of three nitric oxide-releasing compounds and evaluate them as possible therapies for this malignancy. Bladder cancer cell lines T24 and 253J were used to evaluate the antiproliferative, antimigratory, and genotoxic effects of compounds. Moreover, we determined the NF-κB pathway inhibition, and finally, the survivin downregulation exerted by our molecules. The results revealed that compounds 1 and 3 exerted a high antiproliferative activity against bladder cancer cells through DNA damage and survivin downregulation. In addition, compound 3 reduced bladder cancer cell migration. We found that nitric oxide donors are promising molecules for the development of a new therapeutic targeting the underlying mechanisms of tumorigenesis and progression of bladder cancer.


  • Open Access

    PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors

    by Valentina Perini, Michelle Schacke, Pablo Liddle, Salomé Vilchez-Larrea, Deborah J. Keszenman, Laura Lafon-Hughes

    Poly(ADP-ribosyl)polymerase (PARP) synthesizes poly(ADP-ribose) (PAR), which is anchored to proteins. PAR facilitates multiprotein complexes’ assembly. Nuclear PAR affects chromatin’s structure and functions, including transcriptional regulation. In response to stress, particularly genotoxic stress, PARP activation facilitates DNA damage repair. The PARP inhibitor Olaparib (OLA) displays synthetic lethality with mutated homologous recombination proteins (BRCA-1/2), base excision repair proteins (XRCC1, Polβ), and canonical nonhomologous end joining (LigIV). However, the limits of synthetic lethality are not clear. On one hand, it is unknown whether any limiting factor of homologous recombination can be a synthetic PARP lethality partner. On the other hand, some BRCA-mutated patients are not responsive to OLA for still unknown reasons. In an effort to help delineate the boundaries of synthetic lethality, we have induced DNA damage in VERO cells with the radiomimetic chemotherapeutic agent bleomycin (BLEO). A VERO subpopulation was resistant to BLEO, BLEO + OLA, and BLEO + OLA + ATM inhibitor KU55933 + DNA-PK inhibitor KU-0060648 + LigIV inhibitor SCR7 pyrazine. Regarding the mechanism(s) behind the resistance and lack of synthetic lethality, some hypotheses have been discarded and alternative hypotheses are suggested.